65,007 Shares in Bristol Myers Squibb Company $BMY Purchased by B.A. Schrock Wealth Management Inc.

Posted by Francis Steltz on Oct 15th, 2026

B.A. Schrock Wealth Management Inc. acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 65,007 shares of the biopharmaceutical company’s stock, valued at approximately $3,995,000. Bristol Myers Squibb accounts for 1.3% of B.A. Schrock Wealth Management Inc.’s portfolio, making the stock its 23rd biggest holding.

Other large investors also recently bought and sold shares of the company. Davis Asset Management L.P. purchased a new stake in Bristol Myers Squibb in the second quarter worth $27,000. Addison Advisors LLC bought a new stake in shares of Bristol Myers Squibb during the second quarter worth $32,000. Bayban purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at $31,000. Groupe la Francaise boosted its stake in shares of Bristol Myers Squibb by 562.9% during the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 501 shares during the period. Finally, Kilter Group LLC bought a new position in shares of Bristol Myers Squibb in the second quarter worth about $35,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 4.7%

NYSE:BMY opened at $59.34 on Thursday. The firm has a 50-day simple moving average of $63.72 and a 200-day simple moving average of $60.28. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64. The firm has a market cap of $121.22 billion, a P/E ratio of 13.07, a P/E/G ratio of 0.28 and a beta of 0.19. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period last year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.70 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Rothschild & Co Redburn raised their price target on shares of Bristol Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research note on Thursday, October 8th. HSBC reissued a “hold” rating and issued a $65.00 price objective (up from $60.00) on shares of Bristol Myers Squibb in a research report on Thursday, September 10th. Morgan Stanley restated an “underweight” rating and issued a $41.00 target price (up from $40.00) on shares of Bristol Myers Squibb in a research note on Wednesday, October 7th. Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Finally, Citigroup reaffirmed a “neutral” rating and set a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $64.88.

View Our Latest Analysis on BMY

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.05% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Pipeline progress provided the main catalyst. Bristol Myers reported favorable Phase 3 results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, including improved progression-free survival. The data may support upcoming regulatory discussions and strengthen the company’s growth outlook as older blockbuster drugs face competitive pressure. What Could Bristol Myers Squibb BMY Two Phase 3 Wins Change?
Positive Sentiment: Analyst support remains a tailwind. Truist Financial maintained its Buy rating on BMY, signaling confidence in the company’s pipeline and valuation. Bristol Myers’ relatively low earnings multiple and sizeable dividend yield may also attract income-oriented investors. Truist Financial Sticks to Its Buy Rating for Bristol Myers Squibb
Neutral Sentiment: Admilparant results were characterized inconsistently. Reports described the Phase 3 idiopathic pulmonary fibrosis data as either positive or mixed, with favorable efficacy and safety observations but some limitations that could affect regulatory expectations. The conflicting interpretation makes the drug a potential opportunity but not yet a clear near-term catalyst. BMY Reports Mixed Phase III Trial Results
Neutral Sentiment: Investor attention is elevated ahead of quarterly earnings. BMY is scheduled to report third-quarter results later this month, with analysts expecting a single-digit decline in earnings. Recent trial news and the stock’s strong longer-term performance have increased focus on whether results and guidance can support the valuation. Bristol Myers Squibb Quarterly Earnings Preview
Negative Sentiment: Wells Fargo reduced its price target from $65 to $60 and kept an Equal Weight rating. The lower target reflects limited perceived upside and highlights ongoing concerns about earnings growth, patent-related pressure and the need for newer medicines to replace aging blockbusters. Wells Fargo Lowers Bristol Myers Squibb Price Target

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.